FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Poll|August 27, 2021
Poll results: Have you or do you plan to implement myopia control into your practice?
Author(s)Brooke Henson, Editor
See our latest poll results
Advertisement
Optometry Times® polled our audience with the following question from August 13, 2021 to August 27, 2021:
The poll appeared on
36 ODs responded, in total. Of these:
• 19 responded "Yes, would like to start"
• 12 responded "Yes, already doing it"
• 5 responded "No, not interested"
Advertisement
Related to this article
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
2
Takeaways from this week in optometry: October 16-23
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5